Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Anti-IgE: Phase II data; Phase III

DNA published in The New England Journal of Medicine results of a 317-patient Phase II study showing that treatment with Anti-IgE significantly reduced asthma symptom scores after 12

Read the full 282 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE